# A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

> **NCT04258033** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Pearl Biotechnology Limited Liability Company** · enrollment: 145 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PLB1001

## Key facts

- **NCT ID:** NCT04258033
- **Lead sponsor:** Beijing Pearl Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-17
- **Primary completion:** 2024-05-14
- **Final completion:** 2025-12-31
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258033, "A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04258033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*